benserazide has been researched along with oxidopamine in 54 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.85) | 18.7374 |
| 1990's | 11 (20.37) | 18.2507 |
| 2000's | 11 (20.37) | 29.6817 |
| 2010's | 30 (55.56) | 24.3611 |
| 2020's | 1 (1.85) | 2.80 |
| Authors | Studies |
|---|---|
| Ariano, MA; Chase, TN; Engber, TM; Susel, Z | 1 |
| Di Chiara, G; Morelli, M | 1 |
| Chudakova, IV; Hiripi, L; Rózsa, KS | 1 |
| Di Chiara, G; Fenu, S; Morelli, M; Pinna, A | 1 |
| De Klippel, N; Ebinger, G; Herregodts, P; Michotte, Y; Sarre, S | 1 |
| Soares-da-Silva, P | 1 |
| Boldry, RC; Chase, TN; Engber, TM; Kask, AM; Papa, SM | 1 |
| Bonastre, M; Chase, TN; Engber, TM; Marin, C; Papa, S; Tolosa, E | 1 |
| Chang, WY; Webster, RA | 1 |
| Barone, P; DiChiara, G; Morelli, M; Pellecchia, MT; Vallone, D; Verde, P | 1 |
| Honey, CR; Shen, H | 1 |
| Adams, AC; Keefe, KA | 1 |
| Blunt, SB; Datla, KP; Dexter, DT | 1 |
| Andrén, PE; Gunne, L; Klintenberg, R; Svenningsson, P | 1 |
| Arai, A; Kannari, K; Matsunaga, M; Shen, H; Yamato, H | 1 |
| Arai, A; Kannari, K; Maeda, T; Matsunaga, M; Shen, H; Suda, T | 1 |
| Aguilar, E; Bonastre, M; Marin, C; Obeso, JA; Tolosa, E | 1 |
| Funabashi, T; Goshima, Y; Kimura, F; Kuroiwa, Y; Misu, Y; Shimamura, M; Shimizu, M; Yagami, T | 1 |
| Buck, K; Ferger, B | 2 |
| Wang, J; Ye, Q; Yuan, CG; Yuan, CX; Zhang, Y | 1 |
| Aguilar, E; Bartoszyk, GD; Marin, C; Obeso, JA; Rodríguez-Oroz, MC | 1 |
| García-Gutiérrez, MS; Ledent, C; Leiva, C; Leza, JC; Manzanares, J; Molina, JA; Pérez-Nievas, BG; Pérez-Rial, S | 1 |
| Ballion, B; Chetrit, J; Frenois, F; Gonon, F; Murer, MG; Zold, CL | 1 |
| Cenci, MA; Crossman, AR; Kobylecki, C; Ravenscroft, P | 1 |
| Kunselman, AR; Lieu, CA; Manyam, BV; Subramanian, T; Venkiteswaran, K | 1 |
| Auguet, M; Chabrier, PE; Charnet, C; Cornet, S; Roubert, V; Spinnewyn, B | 1 |
| Gil, SJ; Koh, HC; Lee, JE; Minn, YK; Park, CH | 1 |
| Bishop, C; Button, T; Dupre, KB; Eskow Jaunarajs, KL; Ostock, CY; Savage, LM; Wolf, W | 1 |
| Dziubina, A; Gołembiowska, K | 1 |
| Cai, Y; Liu, Z; Ren, T; Wu, N; Yang, X; Yuan, W | 1 |
| Ivanova, EA; Kapitsa, IG; Kokshenev, II; Nepoklonov, AV; Val'dman, EA; Voronina, TA | 1 |
| Geng, XC; Yin, LL; Zhu, XZ | 1 |
| Chao, OY; Huston, JP; Mattern, C; Nikolaus, S; Pum, ME; Ruocco, LA; Silva, AM; Wessler, J | 1 |
| Jackson, MJ; Jairaj, M; Jenner, P; Rose, S; Strang, I; Tayarani-Binazir, KA | 1 |
| Adkins, CE; Cenci, MA; Lockman, PR; Lundblad, C; Ohlin, KE; Sebastianutto, I | 1 |
| Alcacer, C; Gaven, F; Girault, JA; Hervé, D; Santini, E; Valjent, E | 1 |
| Calabresi, P; Costa, C; de Iure, A; Di Filippo, M; Di Luca, M; Gardoni, F; Ghiglieri, V; Latagliata, EC; Marti, M; Morari, M; Pascucci, T; Pendolino, V; Picconi, B; Puglisi-Allegra, S; Sgobio, C; Siliquini, S; Spillantini, MG; Tantucci, M; Tozzi, A | 1 |
| Gerlach, M; Halley, P; Riederer, P; van den Buuse, M | 1 |
| Chen, Y; Hong, X; Liu, Z; Song, L; Wu, N; Yang, X; Yuan, W | 1 |
| Acher, F; Bonito-Oliva, A; Fisone, G; Lopez, S; Pallottino, S | 1 |
| Bonastre, M; Cortés, R; Giralt, A; Marin, C; Mengod, G; Obeso, JA; Schapira, AH | 1 |
| Che, JY; Gan, J; Liu, ZG; Song, L; Wang, WW; Xie, CL; Yuan, ML; Yuan, WE; Zhang, SF | 1 |
| Bordia, T; Drenan, RM; McGregor, M; McIntosh, JM; Quik, M | 1 |
| Chen, C; Fan, Q; Huang, J; Pan, X; Wei, H | 1 |
| De Wolf, C; Downey, P; Michel, A; Scheller, D; Schwarting, R; Van Damme, X | 1 |
| Abe, H; Ebihara, K; Ikarashi, Y; Imamura, S; Ishida, Y; Kase, Y; Koganemaru, G; Mizoguchi, K; Sekiguchi, K; Tabuchi, M | 1 |
| Black, MA; Dearden, PK; Duncan, EJ; Gemmell, NJ; Parr-Brownlie, LC; Reynolds, JN; Smith, LM | 1 |
| Geng, X; Han, H; Hou, Y; Lei, C; Li, M; Wang, M; Wang, X; Xie, J; Yao, X; Zhang, Q; Zhang, X | 1 |
| Antonioli, L; Ballabeni, V; Barocelli, E; Bernardini, N; Blandini, F; Blandizzi, C; Cerri, S; Colucci, R; Fornai, M; Gentile, D; Ippolito, C; Levandis, G; Pellegrini, C; Segnani, C; Tirotta, E | 1 |
| Deng, M; Fang, Y; Gui, X; Huang, L; Lu, S; Zhang, S | 1 |
| Hoshino, N; Ishikawa, T; Muraoka, S; Nishimura, T; Okano, M; Satoyoshi, H; Takahata, K; Tsunekawa, H | 1 |
| Denibaud, AS; Drieu La Rochelle, C; Loiodice, S; Méot, B; Montagne, P; Rion, B; Viel, R; Wing Young, H | 1 |
| Furukawa, T; Kinoshita, I; Kon, T; Murakami, Y; Nakamura, T; Nishijima, H; Suzuki, C; Tomiyama, M | 1 |
54 other study(ies) available for benserazide and oxidopamine
| Article | Year |
|---|---|
Striatal D1 dopamine receptor morphochemistry following continuous or intermittent L-dopa replacement therapy.
Topics: Animals; Benserazide; Benzazepines; Corpus Striatum; Drug Administration Schedule; Hydroxydopamines; Levodopa; Male; Microscopy, Fluorescence; Myelin Sheath; Neurotoxins; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1 | 1991 |
MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benserazide; Dizocilpine Maleate; Dopamine Agents; Ergolines; Hydroxydopamines; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease, Secondary; Quinpirole; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereoisomerism; Stereotyped Behavior | 1990 |
Effect of benserazid and 6-hydroxydopamine on the development of the last larval instar of the house cricket, Acheta domestica L.
Topics: Animals; Benserazide; Ecdysone; Gryllidae; Hydrazines; Hydroxydopamines; Larva; Neurons; Orthoptera; Oxidopamine | 1986 |
Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adenosine; Animals; Antihypertensive Agents; Autoradiography; Basal Ganglia; Benserazide; Binding Sites; Dopamine Agents; Ergolines; Levodopa; Male; Neural Pathways; Neurons; Oxidopamine; Phenethylamines; Quinolinic Acid; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Purinergic P1; Stereotyped Behavior | 1994 |
Biotransformation of locally applied L-dopa in the corpus striatum of the hemi-parkinsonian rat studied with microdialysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Biotransformation; Corpus Striatum; Denervation; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Homovanillic Acid; Levodopa; Male; Microdialysis; Nomifensine; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Tetrodotoxin | 1994 |
Preferential decarboxylation of L-threo-3,4-dihydroxyphenylserine in rat renal tissues.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Droxidopa; Heart Ventricles; Jejunum; Kidney; Kidney Cortex; Liver; Male; Methoxyhydroxyphenylglycol; Norepinephrine; Oxidopamine; Rats; Rats, Wistar | 1993 |
Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade.
Topics: Animals; Antiparkinson Agents; Apomorphine; Benserazide; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Injections; Injections, Intraventricular; Levodopa; Male; Movement; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Rotation; Stereotyped Behavior; Substantia Nigra | 1995 |
MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Dizocilpine Maleate; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Prosencephalon; Rats; Rats, Sprague-Dawley; Rotation | 1996 |
Effect of L-dopa alone and with benserazide on the spontaneous activity of striatal neurones in normal and 6-hydroxydopamine-lesioned rats.
Topics: Animals; Benserazide; Drug Interactions; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Visual Cortex | 1997 |
Behavioural sensitization in 6-hydroxydopamine-lesioned rats is related to compositional changes of the AP-1 transcription factor: evidence for induction of FosB- and JunD-related proteins.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benserazide; Cell Nucleus; Corpus Striatum; Denervation; Dizocilpine Maleate; Gene Expression Regulation; Levodopa; Male; Motor Activity; Neurons; Oxidopamine; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Rats; Rats, Sprague-Dawley; Rotation; Stereotyped Behavior; Transcription Factor AP-1 | 1997 |
Circling behaviour in 6-hydroxydopamine-lesioned rats given pulsed levodopa is reduced more by lesions in the entopeduncular nucleus/substantia nigra pars reticulata than in the subthalamic nucleus.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Apomorphine; Benserazide; Corpus Striatum; Dopamine Agents; Dopamine Agonists; Injections, Intraperitoneal; Levodopa; Male; Motor Activity; Oxidopamine; Quinolinic Acid; Rats; Rats, Wistar; Substantia Nigra; Thalamic Nuclei | 1998 |
Buprenorphine potentiates L-DOPA-induced contralateral rotation in 6-hydroxydopamine-treated rats.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Benserazide; Buprenorphine; Drug Synergism; Injections, Intraventricular; Levodopa; Male; Motor Activity; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptors, Opioid | 1999 |
Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Chlorides; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Ferric Compounds; Immunoenzyme Techniques; Levodopa; Male; Neostriatum; Nerve Net; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra; Tyrosine 3-Monooxygenase | 2001 |
Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Callithrix; Dopamine; Dopamine Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalins; Female; In Situ Hybridization; Levodopa; Male; Motor Activity; Naloxone; Narcotic Antagonists; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; RNA; Rotation; Stereotyped Behavior; Sympathectomy, Chemical | 2002 |
Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Brain; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Humans; Levodopa; Male; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Time Factors | 2003 |
Amantadine increases L-DOPA-derived extracellular dopamine in the striatum of 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Amantadine; Analysis of Variance; Animals; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Corpus Striatum; Dialysis; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Extracellular Space; Levodopa; Male; Oxidopamine; Rats; Rats, Wistar; Time Factors | 2003 |
Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.
Topics: Animals; Benserazide; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Models, Animal; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Male; Nitriles; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Treatment Outcome | 2005 |
L-3,4-dihydroxyphenylalanine-induced c-Fos expression in the CNS under inhibition of central aromatic L-amino acid decarboxylase.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Cell Count; Central Nervous System; Dopamine Agents; Drug Interactions; Enzyme Inhibitors; Functional Laterality; Gene Expression Regulation; Hydrazines; Immunohistochemistry; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley | 2006 |
Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Behavior, Animal; Benserazide; Brain Injuries; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Homovanillic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Rats; Rats, Wistar | 2008 |
[Effects of traditional Chinese herbal medicine on the neurobehavioral manifestations and the activity of dopamine D2 receptor in corpora striatum of rats with levodopa-induced dyskinesias].
Topics: Animals; Benserazide; Corpus Striatum; Drugs, Chinese Herbal; Dyskinesias; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Phytotherapy; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2 | 2008 |
Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
Topics: Analysis of Variance; Animals; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Microdialysis; Norepinephrine; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Severity of Illness Index | 2009 |
Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
Topics: Animals; Apomorphine; Benserazide; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Male; Microinjections; Organic Chemicals; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Rotation; Serotonin Receptor Agonists; Stereotyped Behavior; Subthalamic Nucleus; Sympathectomy, Chemical; Sympatholytics | 2009 |
Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors.
Topics: Amphetamine; Analysis of Variance; Animals; Benserazide; Brain; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; In Situ Hybridization; Levodopa; Lipid Peroxidation; Male; Mice; Mice, Knockout; Motor Activity; Neurons; Oxidopamine; Receptor, Cannabinoid, CB1; Severity of Illness Index | 2011 |
D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Action Potentials; Animals; Antiparkinson Agents; Apomorphine; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2009 |
Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Adamantane; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Brain; Calcium; Callithrix; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, AMPA | 2010 |
A water extract of Mucuna pruriens provides long-term amelioration of parkinsonism with reduced risk for dyskinesias.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Benserazide; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Forelimb; Mucuna; Oxidopamine; Parkinsonian Disorders; Phytotherapy; Plant Extracts; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Rotation; Time Factors; Tyrosine 3-Monooxygenase; Vibrissae | 2010 |
An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
Topics: Adenosine A2 Receptor Antagonists; Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Biological Assay; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Administration Schedule; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Placebos; Purines; Random Allocation; Rats; Reproducibility of Results; Rotation; Sample Size; Single-Blind Method; Sympatholytics | 2011 |
Positive association between striatal serotonin level and abnormal involuntary movements in chronic L-DOPA-treated hemiparkinsonian rats.
Topics: Animals; Benserazide; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin | 2011 |
Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Benserazide; Benzazepines; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induced; Glutamic Acid; Levodopa; Male; Microdialysis; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists | 2011 |
Effect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Benserazide; Caffeine; Dopamine; Glutamic Acid; Hydroxyl Radical; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Adenosine A2A; Triazines; Triazoles | 2012 |
Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Delayed-Action Preparations; Disease Models, Animal; Dopamine Agents; Drug Combinations; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Reaction Time | 2011 |
[Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].
Topics: Adamantane; Amantadine; Animals; Behavior, Animal; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Substantia Nigra | 2011 |
The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Benserazide; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; RGS Proteins | 2011 |
Intranasally applied L-DOPA alleviates parkinsonian symptoms in rats with unilateral nigro-striatal 6-OHDA lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dopamine; Electrochemistry; Exploratory Behavior; Forelimb; Functional Laterality; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Male; Motor Activity; Motor Skills; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra; Sympatholytics | 2012 |
Benserazide dosing regimen affects the response to L-3,4-dihydroxyphenylalanine in the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Levodopa; Male; Microinjections; Motor Activity; Oxidopamine; Rats; Rats, Wistar; Time Factors | 2012 |
Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.
Topics: Algorithms; Animals; Antiparkinson Agents; Autoradiography; Basal Ganglia; Behavior, Animal; Benserazide; Blood-Brain Barrier; Capillaries; Cerebrovascular Circulation; Dyskinesias; Female; Glucose; Immunohistochemistry; Intermediate Filament Proteins; Levodopa; Nerve Tissue Proteins; Nestin; Oxidopamine; Parkinson Disease, Secondary; Permeability; Rats; Rats, Sprague-Dawley; Sympatholytics; Tyrosine 3-Monooxygenase | 2012 |
Gα(olf) mutation allows parsing the role of cAMP-dependent and extracellular signal-regulated kinase-dependent signaling in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Brain; Corpus Striatum; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Functional Laterality; GTP-Binding Protein alpha Subunits; Histones; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Movement; Mutation; Oxidopamine; Psychomotor Performance; Receptors, AMPA; Signal Transduction; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase | 2012 |
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease.
Topics: alpha-Synuclein; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Biophysical Phenomena; Disease Models, Animal; Dopamine; Electric Stimulation; Excitatory Postsynaptic Potentials; Exploratory Behavior; Hippocampus; Humans; Levodopa; Long-Term Potentiation; Male; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microdialysis; Mutation; Oxidopamine; Parkinson Disease; Patch-Clamp Techniques; Radionuclide Imaging; Rats; Subcellular Fractions; Sympatholytics; Synaptosomes; Tritium; Tyrosine 3-Monooxygenase | 2012 |
The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.
Topics: Adrenergic Agents; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Antiparkinson Agents; Benserazide; Clonidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dystonia; Facial Asymmetry; Idazoxan; Levodopa; Locomotion; Oxidopamine; Parkinson Disease; Piribedil; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Statistics, Nonparametric; Upper Extremity | 2013 |
Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Blotting, Western; Delayed-Action Preparations; Disease Models, Animal; Down-Regulation; Drug Carriers; Drug Combinations; Dyskinesia, Drug-Induced; Female; Lactic Acid; Levodopa; Microspheres; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Receptors, AMPA | 2012 |
Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Aminobutyrates; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Gene Expression Regulation; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease; Phosphinic Acids; Receptors, Metabotropic Glutamate; Time Factors | 2011 |
Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Benserazide; Benzothiazoles; Corpus Striatum; Hippocampus; Levodopa; Male; Motor Activity; Neurogenesis; Oxidopamine; Parkinsonian Disorders; Pramipexole; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D3; Substantia Nigra; Time Factors | 2014 |
Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.
Topics: Adrenergic Agents; Animals; Benserazide; Blotting, Western; Corpus Striatum; Cyclic AMP-Dependent Protein Kinases; Dopamine Agents; Drug Combinations; Dyskinesias; Female; Fluorescent Antibody Technique; Lactic Acid; Levodopa; Microspheres; Neurons; Oxidopamine; Parkinson Disease; Phosphoproteins; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; tau Proteins; Transcription Factors | 2014 |
Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Cocaine; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Transgenic; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinsonian Disorders; Protein Binding; Receptors, Nicotinic | 2015 |
Neuroprotective effect of combined therapy with hyperbaric oxygen and madopar on 6-hydroxydopamine-induced Parkinson's disease in rats.
Topics: Animals; Apomorphine; Benserazide; Combined Modality Therapy; Drug Combinations; Glial Fibrillary Acidic Protein; Glutathione Peroxidase; Hyperbaric Oxygenation; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Nerve Degeneration; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-bcl-2; Rats, Wistar; Stereotyped Behavior; Substantia Nigra; Superoxide Dismutase; Tyrosine 3-Monooxygenase | 2015 |
Behavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs.
Topics: Adenosine A2 Receptor Antagonists; Animals; Benserazide; Benzothiazoles; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Combinations; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Receptors, N-Methyl-D-Aspartate | 2015 |
Yokukansan, a Traditional Japanese Medicine, Enhances the L-DOPA-Induced Rotational Response in 6-Hydroxydopamine-Lesioned Rats: Possible Inhibition of COMT.
Topics: Animals; Benserazide; Catechols; Cell Line; Corpus Striatum; Dopamine; Drugs, Chinese Herbal; Hydrazines; Levodopa; Male; Medicine, East Asian Traditional; Nitriles; Oxidopamine; Pargyline; Rats; Rats, Wistar | 2016 |
Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat.
Topics: Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Cytoskeleton; Drug Combinations; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Random Allocation; Rats, Wistar; RNA, Messenger; Tyrosine 3-Monooxygenase | 2016 |
Effect of l-DOPA on local field potential relationship between the pedunculopontine nucleus and primary motor cortex in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Benserazide; Conditioning, Operant; Disease Models, Animal; Evoked Potentials; Fourier Analysis; Levodopa; Locomotion; Male; Motor Cortex; Oxidopamine; Parkinson Disease; Pedunculopontine Tegmental Nucleus; Rats; Rats, Wistar; Time Factors | 2016 |
Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration.
Topics: Acetylcholine; Administration, Oral; Animals; Antiparkinson Agents; Benserazide; Choline O-Acetyltransferase; Colon; Gastrointestinal Transit; Inflammation; Interleukin-1beta; Levodopa; Male; Muscle, Smooth; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; Synaptic Transmission; Tissue Culture Techniques; Tumor Necrosis Factor-alpha | 2017 |
β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Antiparkinson Agents; Behavior, Animal; Benserazide; Catechol O-Methyltransferase; Corpus Striatum; Dopa Decarboxylase; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Drug Combinations; Drug Therapy, Combination; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2017 |
Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
Topics: Animals; Antiparkinson Agents; Benserazide; Cytoskeletal Proteins; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Movement; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RNA, Messenger; Selegiline; Time Factors | 2018 |
Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease.
Topics: Amphetamine; Animals; Antiparkinson Agents; Anxiety; Benserazide; Disease Models, Animal; Dopamine; Forelimb; Gait Disorders, Neurologic; Interpersonal Relations; Levodopa; Locomotion; Male; Maze Learning; Memory Disorders; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Recognition, Psychology; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 2019 |
Altered amantadine effects after repetitive treatment for l-dopa-induced involuntary movements in a rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2023 |